Quotables
"Fooling around with alternating current is just a waste of time. Nobody will use it, ever."
Thomas Edison ; 1889
PatentStorm News
Make the Most of PatentStorm
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest patents by subscribing to an RSS feed.
Got questions? Ask a Patent Expert!
Registered users: Manage your profile, comments and alerts.
| Number | Title | Issue Date |
| 7618986 | Method of treating latent tuberculosis 2-Nitroimidazolyl-alkylaminoquinolines, and compositions containing the same, useful in the treatment of tuberculosis are disclosed. Methods of treating tuberculosis using the 2-nitroimidazolyl-alkylaminoquinolines, and compositions containing the same, also are dis... | 11/17/2009 |
| 7608628 | Alkylsulphonamide quinolines Compounds of Formula II wherein R1, A, R2, R3, R4, R5, R8, n, m and q are as described in the specification, pharmaceutically-acceptable salts, methods of ma... | 10/27/2009 |
| 7585878 | Benzamide derivative or salt thereof There is provided a compound having a capsaicin receptor VR1 inhibitory activity and useful as a therapeutic agent for various pains including inflammatory pain and neurogenic pain, migraine, cluster headache, bladder diseases including overactive bladder, and the l... | 09/08/2009 |
| 7550482 | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors The invention relates to ethynyl-substituted tetrahydroquinolinone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR modu... | 06/23/2009 |
| 7550483 | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same An amorphous form of a salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide. ... | 06/23/2009 |
| 7531554 | 4-oxoquinoline compound and use thereof as HIV integrase inhibitor Provision of a compound having an anti-HIV activity, particularly an integrase inhibitory activity. A 4-oxoquinoline compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof: wh... | 05/12/2009 |
| 7524862 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds Alkyne compounds of formula I wherein A, B, W, X, Y, Z, R1, and R2 have the meanings given herein, which have MCH-receptor antagonistic activity and are useful for preparing pharmaceutical compositions... | 04/28/2009 |
| 7507750 | Stabilized ascorbic acid derivative An ascorbic acid derivative, which is a compound represented by the following general formula (1) or a salt thereof: [Chemical Formula 11] (wherein X and Y each represents H or a protective group for OH, R1 | 03/24/2009 |
| 7488740 | Substituted quinolin-4-ylamine analogues Substituted quinolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation... | 02/10/2009 |
| 7468379 | Inhibition of osteolytic lesions by SRC kinase inhibitors The present invention include methods and compositions for treating bone-resorbing diseases or bone resorption related to a pathologic condition generally, including, but not limited to osteoporosis, arthritis, rheumatoid arthritis, cancer metastases to the bone, bo... | 12/23/2008 |
| 7449479 | Hepatitis C virus inhibitors Hepatitis C virus inhibitors are disclosed having the general formula: wherein R1, R2, R3, R′, B, Y and X are described in the description. Compositions comprising the compounds an... | 11/11/2008 |
| 7442710 | Substituted phenyl methanones The present invention relates to compounds of general formula IA or IB wherein X1 and X2 are each independently N or C—R″ and R1, R2,R3, R... | 10/28/2008 |
| 7425564 | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus prolifertor receptor and medicinal composition containing the same An objective of the present invention is to provide compounds having potent antitumor activity. The compounds of the present invention are represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: ... | 09/16/2008 |
| 7417056 | 5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents Compounds of general formula (IIa) or (IIb) and their use as pharmaceutical agents. ... | 08/26/2008 |
| 7417148 | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) Compounds of the formula: wherein: n is an integer from 1-3; X is N, CH, provided that when X is N, n is 2 or 3; R is alkyl of 1 to 3 carbon atoms; R1 is 2,4... | 08/26/2008 |
| 7414037 | Hydrazide-containing CFTR inhibitor compounds and uses thereof The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions a... | 08/19/2008 |
| 7402683 | Cinnamic acid amides The present invention relates to compounds, to processes for preparing them, to pharmaceutical compositions comprising them, and to their use in the therapy and/or prophylaxis in illnesses in people or animals, especially diseases of bacterial infection. ... | 07/22/2008 |
| 7402674 | 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments The invention relates to 7-phenylamino-4-quinolone-3-carboxylic acid derivatives and to the physiologically tolerated salts and physiologically... | 07/22/2008 |
| RE40418 | Treatment of neoplasms with CCI-779/EKB-569 combination This invention provides the use of a combination of CCI-779 and EKB-569 in the treatment of neoplasms. ... | 07/01/2008 |
| 7384958 | Quinoline inhibitors of cGMP phosphodiesterase Compounds of the formula (I) are useful as inhibitors of cGMP PDE especially Type 5. ... | 06/10/2008 |
| 7378430 | Quinoline inhibitors of cGMP phosphodiesterase Compounds of the formula (I) are useful as inhibitors of cGMP PDE especially Type 5. ... | 05/27/2008 |
| 7371763 | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas The invention relates to a group of quinolyl, isoquinolyl and pyridyl ureas, their the use in treating raf mediated diseases, and pharmaceutical compositions which contain these ureas for use in such therapy. ... | 05/13/2008 |
| 7371765 | Quinoline derivatives having VEGF inhibiting activity The invention relates to compounds of formula (I) wherein: either any one of G1, G2, G3, G4 and G5 is nitrogen and the other four are —CH—, or G1, G2, G3, G4 and G... | 05/13/2008 |
| 7371731 | Methods for using glucose pentasulfate for treating amyloid associated with type II diabetes A pharmaceutical agent for treating an amyloid disease in a patient, wherein the pharmaceutical agent comprises glucose pentasulfate or a pharmaceutically acceptable salt thereof. The agent is directed to amyloid diseases in general and to type II diabetes in partic... | 05/13/2008 |
| 7368573 | Triamide-substituted heterobicyclic compounds This invention relates to MTP/Apo-B secretion inhibitors of Formula (I) wherein R1-R7, X1, m and n are as defined in the specification, as well as pharmaceutical compositions comprising the ... | 05/06/2008 |
| 7364752 | Solid dispersion pharamaceutical formulations A pharmaceutical composition is disclosed which comprises a solid dispersion of an HIV protease inhibitor in a water soluble carrier, such as PEG, having enhanced bioavailability and improved dissolution properties. The solid dispersion may optionally be encapsulate... | 04/29/2008 |
| 7365081 | Indole derivatives and their use as medicaments The invention relates to novel indole derivatives of the general formula 1, to their preparation and to their use as medicaments, in particular for treating tumors ... | 04/29/2008 |
| 7365203 | Process for the synthesis of 6-amino-4-(3-chloro-4-fluoro-phenylamino)-7-ethoxy-quinoline-3-carbonitrile The present invention provides a process for the preparation of 6-amino-4-(3-chloro-4-fluoro-phenylamino)-7-ethoxy-quinoline-3-carbonitrile comprising the steps and products disclosed within this application. ... | 04/29/2008 |
| 7358222 | Preventing airway mucus production by administration of EGF-R antagonists Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks th... | 04/15/2008 |
| 7354932 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and opt... | 04/08/2008 |
| 7348340 | N-type calcium channel antagonists for the treatment of pain Compounds useful for the treatment of pain in accord with the following structural diagram, wherein R1, R2 and R3 are any of a number of groups as defined in the specification and pharmaceut... | 03/25/2008 |
| 7348338 | PPAR active compounds Compounds are described that are active on PPARs, including pan-active compounds. Also described are methods for developing or identifying compounds having a desired selectivity profile. ... | 03/25/2008 |
| RE40155 | Methods for treatment of benign and malignant tumors, including lymphomas, leukemias, and leiomyomas In a preferred embodiment, drugs having chemotherapeutic properties which are useful against certain neoplastic disorders with wide safety margins as evidenced by their low toxicity, and molecular actions. Such drugs include as active ingredient(s) one or more N-sub... | 03/18/2008 |
| 7342026 | Substituted quinolines for the treatment of protozoa and retrovirus co-infections The invention relates to the use of quinolines having general formula (I), wherein R1 denotes H; alkyl C1-C15; alkenyl or alkynyl C2-C15; —CHO; heteroaryl; alkyl C1-C15 or alkenyl or alky... | 03/11/2008 |
| 7335491 | Production of anti-abeta An improved system for large scale production of proteins and/or polypeptides in cell culture, particularly in media characterized by one or more of: i) a cumulative amino acid concentration greater than about 70 mM; ii) a molar cumulative glutamine to cumulative as... | 02/26/2008 |
| 7320989 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists The present invention relates to urotensin II receptor antagonists, pharmaceutical compositions containing them and their use. ... | 01/22/2008 |
| 7317024 | Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof The invention relates to a class of novel non-steroidal compounds which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have th... | 01/08/2008 |
| 7312233 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions ... | 12/25/2007 |
| 7312234 | Chemokine receptor binding heterocyclic compounds Tertiary amines containing a multiplicity of heteroaromatic substituents are useful as chemokine receptor modulators. ... | 12/25/2007 |
| 7312230 | Carboxylic acid derivatives as IP antagonists This invention relates to compounds which are generally IP receptor antagonists and which are represented by Formula I: wherein: R1, R2, and R3 ... | 12/25/2007 |